ESTRO 2024 - Abstract Book

S1124

Clinical - Gynaecology

ESTRO 2024

survival benefit of chemoradiotherapy increased slightly, most evident in women with stage III disease. Regarding the molecular subtypes, patients with p53abn and (hormone receptor negative) NSMP tumours seem to benefit most from chemoradiotherapy. There were few recurrences during long-term follow-up in both treatment arms.

Keywords: Endometrial cancer, chemoradiotherapy, long-term

3560

Proffered Paper

A Phase 3 Study of Pembrolizumab + Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer

Annamaria Cerrotta 1 , Gabriella Macchia 2 , Melissa Christiaens 3 , Susan Lalondrelle 4 , Xiang Zhang 5 , Andréia Cristina De Melo 6 , Klaudia Reginacova 7 , Limor Helpman 8 , Ali Ayhan 9 , Flora Zagouri 10 , Linn Woelber 11 , Kristina Hellman 12 , Nicoletta Colombo 13 , Margarita Romeo Marin 14 , Regina Berger 15 , Karla Alejandra Lopez 16 , Vincent Castonguay 17 , Kazuhiro Takehara 18 , Ting-Chang Chang 19 , Karin Yamada 20 , Sarper Toker 20 , Kan Li 20 , Domenica Lorusso 21 1 Radiotherapy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 2 Radiation Oncology Unit, Responsible Research Hospital, Campobasso, Italy. 3 Department of Radiation-Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium. 4 Department of Clinical Oncology, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research London, London, United Kingdom. 5 Department of Gynecological Oncology, Zhejiang Cancer Hospital, Hangzhou, China. 6 Division of Clinical Research and Technological Development, Brazilian National Cancer Institute, Rio de Janeiro, Brazil. 7 Department of Oncology, University Hospital Kralovske Vinohrady and Charles University, Third faculty of medicine, Prague, Czech Republic. 8 Department of Oncology, Tel Aviv University and Sheba Medical Center, Ramat Gan, Israel. 9 Department of Oncology, Turkish Society of Gynecologic Oncology (TRSGO), Başkent University, Ankara, Turkey. 10 Department of Oncology, Alexandra Hospital, Athens, Greece. 11 NOGGO and Department of Gynaecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 12 Department of Gynecologic Cancer, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden. 13 Gynecologic Oncology Program, European Institute of Oncology, IRCSS, Department of Medicine and Surgery, University of Milano Bicocca, Milan, Italy. 14 Department of Medical Oncology, B-ARGO group, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain. 15 Department for Gynecology and Obstetrics, Medical University of Innsbruck, Arbeitsgemeinschaft Gynäkologische Onkologie Österreich (AGO Austria), Innsbruck, Austria. 16 Department of Oncology, Oncomedica, Guatemala City, Guatemala. 17 Department of Oncology, Centre-Hospitalier-Universitaire-de-Quebec, Laval University, Quebec City, QC, Canada. 18 Department of Gynecologic Oncology, NHO Shikoku Cancer Center, Ehime, Japan. 19 Department of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital and Chang Gung University Medical College, Kueishan, Taoyuan City, Taiwan. 20 Department of Oncology, Merck & Co., Inc., Rahway, NJ, USA. 21 Gynaecology Oncology Unit, Fondazione Policlinico Universitario A Gemelli IRCCS and Catholic University of Sacred Heart, Rome, Italy

Purpose/Objective:

Since 1999, standard therapy for patients with locally advanced cervical cancer (LACC) has been represented by external beam radiotherapy (EBRT) with concurrent chemotherapy followed by brachytherapy. Preclinical and clinical data suggest that the effect of chemoradiotherapy may be enhanced by immunotherapy. Pembrolizumab